Medsamic (Tranexamic Acid)

Tranexamic acid blocks the conversion of plasminogen to plasmin by binding to lysine‑binding sites, thereby inhibiting fibrinolysis. This stabilizes existing fibrin clots and reduces the breakdown of clots, helping to control bleeding without directly altering the clotting cascade.

The dosage of Medsamic is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and clinical setting. Healthcare professionals set the appropriate dose and administration schedule according to current medical guidelines.

The safety of tranexamic acid in pregnancy and lactation has not been definitively established. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Medsamic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Medsamic (tranexamic acid) is a synthetic lysine analogue that offers a predictable pharmacokinetic profile and is widely used for both surgical and non‑surgical bleeding. Compared with agents such as epsilon‑aminocaproic acid, tranexamic acid generally provides stronger antifibrinolytic activity with a similar safety profile, though individual patient factors guide selection.

Medsamic should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

Medsamic is supplied as an injectable solution for intravenous administration. It is typically given as a slow IV infusion or bolus, depending on the clinical protocol, and should be administered by qualified healthcare personnel in a controlled setting.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, seizures (particularly in patients with renal impairment or high plasma concentrations), severe allergic reactions, and rare visual disturbances that may lead to vision loss.

Medsamic is contraindicated in patients with active intravascular clotting disorders, disseminated intravascular coagulation, or known hypersensitivity to tranexamic acid. Caution is also advised for individuals with severe renal impairment or a history of thromboembolic disease.